Prices for brand-name prescription treatments used by Medicare patients didn't increase after drugmakers offered the government discounts to help seniors deal with a gap in benefits known as the "doughnut hole," the Government Accountability Office reported. Before the start of the discount program, 77 brand-name treatments increased 36% for Medicare patients within the coverage gap between January 2007 and December 2010, compared with 35% for those not within the gap. From December 2010 to December 2011, prices for both groups increased just 13%.